While changes in the cell cycle regulators, including the amplification of cyclin D, activation of CDK, and loss of p21CIP1 or p27KIP1, may contribute to tumor adaptation to CDK4/6 inhibition, the main resistance is mediated by RB1 inactivation [60,61]. This evidence concerns the gene CDKN1A and neoplasm.